{
    "clinical_study": {
        "@rank": "125908", 
        "acronym": "IREHIV", 
        "arm_group": [
            {
                "arm_group_label": "Vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)", 
                "arm_group_type": "Active Comparator", 
                "description": "Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks."
            }, 
            {
                "arm_group_label": "Placebo tablets", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim with this study is to provide immunotherapy with vitamin D and phenylbutyrate to\n      treatment-naive HIV infected patients to induce important antimicrobial defence mechanisms\n      and decreased inflammation."
        }, 
        "brief_title": "Immune Reconstitution in HIV Disease (IREHIV)", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV Infection", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Adult patients >18 years not subjected to HAART.\n\n        HIV-1 infected patients with CD4 T cells counts >200 cells/ml.\n\n        Detectable plasma viral loads >5000 copies/ml.\n\n        Exclusion Criteria:\n\n        Patients on HAART or other antimicrobial drugs (including bactrim).\n\n        Antimicrobial drug treatment in the past month.\n\n        Patients with medical contra-indication for biopsy such as bleeding tendencies.\n\n        Hypercalcaemia (serum calcium > 2.6 mmol/L) identified at baseline.\n\n        Pregnant and breast feeding women.\n\n        Any known liver or kidney function abnormality, malignancy or patients treated with\n        cardiac glycosides."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01702974", 
            "org_study_id": "IREHIV-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)", 
                "description": "Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.", 
                "intervention_name": "vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo tablets", 
                "description": "Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.", 
                "intervention_name": "Placebo tablets", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Infective Agents", 
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins", 
                "4-phenylbutyric acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV", 
            "cholecalciferol", 
            "sodium phenylbutyrate", 
            "antimicrobial peptides", 
            "immune response", 
            "inflammation"
        ], 
        "lastchanged_date": "October 8, 2012", 
        "location": {
            "contact": {
                "email": "wonamogne@yahoo.com", 
                "last_name": "Wondwossen Amogne, MD", 
                "phone": "251-911406179"
            }, 
            "facility": {
                "address": {
                    "city": "Addis Ababa", 
                    "country": "Ethiopia", 
                    "state": "Lideta sub city"
                }, 
                "name": "Black Lion Hospital (BLH), Addis Ababa University, Faculty of Medicine"
            }, 
            "investigator": [
                {
                    "last_name": "Wondwossen Amogne, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Endale Kassa, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Ethiopia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Immune Reconstitution in HIV Disease Using Antimicrobial Treatment With Vitamin D and Phenylbutyrate", 
        "other_outcome": {
            "description": "An interim analysis will be performed after approx. 75-100 patients have been included into the study.", 
            "measure": "Interim analysis", 
            "safety_issue": "Yes"
        }, 
        "overall_contact": {
            "email": "wonamogne@yahoo.com", 
            "last_name": "Wondwossen Amogne, MD", 
            "phone": "251-911406179"
        }, 
        "overall_contact_backup": {
            "email": "endalekassalulu@gmail.com", 
            "last_name": "Endale Kassa, MD", 
            "phone": "251-911228562"
        }, 
        "overall_official": {
            "affiliation": "Karolinska Institutet", 
            "last_name": "Susanna Brighenti, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ethiopia: Food, Medicine and Health Care Administration and Control Authority of Ethiopia (FMHACA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Plasma HIV viral load will be used to monitor efficacy of vitamin D and phenylbutyrate treatment among treatment-na\u00efve HIV patients at the time of diagnosis (time point 0) and at 4, 8, 16 and 24 weeks after initiation of antimicrobial treatment with vitamin D and phenylbutyrate. The primary endpoint will be assessed at 16 weeks compared to baseline (time point 0).", 
            "measure": "HIV viral load", 
            "safety_issue": "Yes", 
            "time_frame": "0 (baseline) compared to 16 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01702974"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Karolinska Institutet", 
            "investigator_full_name": "Susanna Brighenti", 
            "investigator_title": "Assistant professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall clinical symptoms.\nBody mass index (BMI).\nMid upper arm circumference (MUAC).", 
                "measure": "Clinical secondary endpoints", 
                "safety_issue": "Yes", 
                "time_frame": "0, 4, 8, 16, 24 weeks."
            }, 
            {
                "description": "HIV viral load (0, 4, 8, 24 weeks).\nPeripheral CD4/CD8 T cell counts.\nPlasma levels of vitamin D, LL-37, sCD14, LPS, 16S RNA and cytokine/chemokine profiles.\nCalprotectin in feces.\nInflammation and microbial translocation in colon punch biopsies (0 and 16 weeks).\nFunctional studies of immune cells (PBMCs).", 
                "measure": "Laboratory secondary endpoints", 
                "safety_issue": "Yes", 
                "time_frame": "0, 4, 8, 16, 24 weeks."
            }
        ], 
        "source": "Karolinska Institutet", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Addis Ababa University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Karolinska Institutet", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}